WHO clarifies that one dose of HPV vaccine can cause Zhifei Bio to plummet

A few days ago, the WHO Strategic Advisory Group of Experts on Immunization (SAGE) convened to review the evidence for 1-dose human papillomavirus (HPV) vaccination and concluded that a single dose of HPV vaccine provides reliable protection, comparable to a 2- or 3-dose vaccination regimen
.
On April 14, affected by this, the stock price of related HPV vaccine concept stocks plunged
.
Zhifei Bio fell by more than 15%, Wantai Bio fell by 10.
00%, Watson Bio, Kangtai Bio, CanSino, etc.
fell
.
As of press time, Zhifei Biology reported 112.
99 yuan/share, down 16.
42%, with a total market value of 180.
8 billion yuan; Wantai Biology reported 256.
04 yuan/share, down 10.
00%, with a total market value of 155.
4 billion yuan
.
However, the new SAGE recommendations are based on concerns about the slow introduction of the HPV vaccine into immunization programmes and low overall population coverage, especially in poorer countries
.
Globally, the use of life-saving vaccines has been slow, with coverage well below the 90% target in some countries, with three-dose global coverage of just 13% in 2020, the WHO said
.
Behind the slow rate of HPV vaccination and low coverage, it is also constrained by factors such as insufficient supply and high vaccination costs
.
Some HPV vaccine manufacturers said in an interview with the media that the WHO's proposal is to solve the huge gap between the supply and demand of HPV vaccine, but this proposal does not have legal effect at present, and it is also inconsistent with the vaccination instructions that have been marketed.
, and the latter's vaccination instructions have legal effect
.
In the future, whether the WHO's recommendations can be truly implemented will still have to face the game with the relevant HPV vaccine manufacturers
.